open access

Vol 6, No 4 (2010)
Congress abstract / Abstract
Published online: 2010-12-16
Get Citation

“Meeting after ASCO 2010”, 2–3 July 2010, Gdańsk

Redakcja OwPK
Onkol. Prak. Klin 2010;6(4):202-215.

open access

Vol 6, No 4 (2010)
Sprawozdania z kongresów i zjazdów
Published online: 2010-12-16

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

“Meeting after ASCO 2010”, 2–3 July 2010, Gdańsk

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 4 (2010)

Article type

Congress abstract / Abstract

Pages

202-215

Published online

2010-12-16

Bibliographic record

Onkol. Prak. Klin 2010;6(4):202-215.

Authors

Redakcja OwPK

References (26)
  1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11): 1116–1127.
  2. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6): 567–578.
  3. Posner MR, Hershock DM, Blajman CR, et al. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17): 1705–1715.
  4. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1): 24–35.
  5. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15): 2450–2456.
  6. Mok T, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine. 2009; 361(10): 947–957.
  7. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009; 27(15): 2516–2522.
  8. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26): 4247–4253.
  9. Soon YuY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27(20): 3277–3283.
  10. Wolmark N, Yothers G, et al. O’Connell M.. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009; 27: 18S.
  11. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10): 1411–1419.
  12. DeMatteo R, Ballman K, Antonescu C, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. 2009; 373(9669): 1097–1104.
  13. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival--a Bayesian meta-analysis. Ann Surg Oncol. 1999; 6(1): 109–116.
  14. Gnant M, Mlineritsch B, Schippinger W, et al. ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360(7): 679–691.
  15. Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol. 2005; 23(8): 1623–1626.
  16. Wiedswang G, Borgen E, Kåresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003; 21(18): 3469–3478.
  17. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005; 103(5): 884–891.
  18. Goldhirsch A, Ingle JN, Gelber RD, et al. Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8): 1319–1329.
  19. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer. 2004; 11(3): 267–275.
  20. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol. 2005; 12(1): 10–19.
  21. Pecorelli S, Favalli G, Gadducci A, et al. After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009; 27(28): 4642–4648.
  22. Markman M, Liu PY, Wilczynski S, et al. Southwest Oncology Group, Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003; 21(13): 2460–2465.
  23. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48(2): 202–205.
  24. Oliver RTD, Mason MD, Mead GM, et al. MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366(9482): 293–300.
  25. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002; 20(22): 4448–4452.
  26. Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003; 10(7): 754–761.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl